SCHEMBL9924258

SCHEMBL9924258

COc1cccc(C(=O)/N=C(/Nc2cc(F)cc(Cl)c2)NC2CCC(NC(=O)c3ccccc3)CC2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.47
CCR3 P51677 1/20 0.45
NPC1 O15118 5/20 0.44
CXCR6 O00574 1/20 0.42
ALDH1A1 P00352 2/20 0.42
TSHR P16473 1/20 0.42
KCNK3 O14649 1/20 0.42
KCNK9 Q9NPC2 1/20 0.42
MCHR1 Q99705 3/20 0.42
RAB9A P51151 4/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
POLB P06746 2/20 0.42
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42
CYP1A2 P05177 1/20 0.42
HSP90AA1 P07900 1/20 0.42
HSP90AB1 P08238 1/20 0.42
HSPA1A P0DMV8 1/20 0.42
CYP2D6 P10635 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9924330 0.92 GRM5 (0.47) GRM5CCR3NPC1CXCR6ALDH1A1
SCHEMBL9924257 0.91 GRM5 (0.42) GRM5CCR3NPC1CXCR6ALDH1A1
SCHEMBL9924333 0.89 NPC1 (0.44) GRM5CCR3NPC1MCHR1RAB9A
SCHEMBL9924331 0.87 NPC1 (0.40) GRM5CCR3NPC1CXCR6ALDH1A1
SCHEMBL9924457 0.87 NPC1 (0.43) GRM5CCR3NPC1MCHR1RAB9A
SCHEMBL9924083 0.86 NPC1 (0.44) GRM5CCR3NPC1MCHR1RAB9A
SCHEMBL9924071 0.86 KMT2A (0.43) GRM5NPC1ALDH1A1TSHRMCHR1
SCHEMBL9924070 0.85 GRM4 (0.40) ALDH1A1MEN1KMT2ACYP2D6
SCHEMBL9924332 0.81 SLC6A9 (0.41) GRM5CCR3NPC1CXCR6RAB9A
SCHEMBL9924222 0.80 CYP2D6 (0.44) GRM5NPC1TSHRRAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
WO-2012078867-A2 CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2012-06-14 WO disclosed